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1. Introductıon 
Antiphospholipid syndrome(APLS) is a prothrombotic state characterized by recurrent 
venous thrombotic events including deep venous thrombosis, as well as pulmonary 
embolism, arterial thrombosis, recurrent fatal loss due to placental thrombosis and the 
presence of circulating antiphospholipid antibodies(APA) (Roubey RAS, 2001). As both 
thrombosis and pregnancy morbidity have a large number of other origins, the diagnosis of 
APLS relies on the quality and reliability of the laboratory investigations, on the persistent 
positivity of the APA assays, and sometimes on the lack of any other cause. Although a 
broad spectrum of APA exists, the universally accepted diagnostic APA tests are lupus 
anticoagulant(LA) functional coagulation assay; anticardiolipin antibody(ACA) enzyme-
linked immunosorbent assay(ELISA); and anti-ǃ2-glycoprotein I antibody(aǃ2GPI) ELISA.  
Antiphospholipid antibodies were first described in 1906 in patients with syphilis. These 
complement-fixing antibodies reacting with extracts from bovine hearts(mitochondrial 
phospholipid cardiolipin) formed the basis for the serologic syphilis test(Venereal Disease 
Research Laboratory-VDRL assay). Mass population screening for syphilis demonstrated 
that patients with systemic lupus erythematosus(SLE) without clinical syphilis had 
persistently false-positive VDRL tests(Haserick J,et al 1952, Baker WF, et al 2008). As false-
positive VDRL tests in patients with SLE were also found to be associated with prolonged in 
vitro coagulation, the term ‘lupus anticoagulant’ was introduced.  
The lupus anticoagulant is an antibody that prolongs phospholipid dependent coagulation 
tests in vitro. It was given this name in 1972 because clear proof of its site of action was 
lacking, and because the anticoagulant had been recognized in patients with systemic lupus 
erythematosus(Donald I Feinstein 2009 ). It is a misnomer because the lupus anticoagulant is 
more frequently encountered in patients without lupus and is associated with thrombosis 
rather than with bleeding. Immunoglobulins reacting with other hemostatic factors, such as 
von Willebrand factor (VWF), factor VIII, factor IX, and factor XI, inhibitors of thrombin and 
fibrin polymerization, and factor XIII have also been described in patients with SLE(Donald 
I Feinstein 2009), but they are rare compared with the lupus anticoagulant. 
Patients with the lupus anticoagulant who do not have established SLE fall into several 
different categories: (1) patients with “lupus-like”chronic autoimmune disorders but 
without findings that fit the criteria for the diagnosis of SLE; (2) patients with other chronic 
systemic autoimmune disorders; (3) patients presenting with a venous or arterial thrombotic 
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event for which no underlying cause may be apparent; (4) patients receiving certain drugs, 
including procainamide and phenothiazines(a high prevalence of the lupus anticoagulant 
and a positive antinuclear antibody test are observed in psychotic patients receiving long-
term chlorpromazine therapy); other drugs or biologics that can induce the lupus 
anticoagulant include hydralazine, quinidine, and possibly ǂ-interferon; (5) patients with a 
recent acute viral infection, in whom the antibody is usually transient; (6) patients with 
human immunodeficiency virus infection; (7) women with recurrent fetal wastage;(8) 
occasionally in older patients with malignancies and (9) patients seeking medical attention 
for a variety of disorders in whom the lupus anticoagulant is discovered as an incidental 
finding, usually discovered because of a prolonged partial thromboplastin time (PTT) 
performed as a routine preoperative evaluation. 
2. Epidemiology 
APA can be detected in the absence of thrombosis or pregnancy morbidity or other systemic 
autoimmune diseases. During ongoing infectious disease, during treatments with a variety of 
drugs and even in healthy individuals, APA positivity may occur. The prevalence of APA 
ranges from 1% to 10% in the general population, 16% in patients with rheumatoid arthritis, 
and 30% to 40% in patients with SLE(Petri M 2000, Lim W et al 2006). The prevalence of 
positive tests for lupus anticoagulant and anticardiolipin antibody in a normal population has 
been reported in several studies. Because of the non-Gaussian distribution of anticardiolipin 
antibody levels in normal subjects, the cut-off points between normal and abnormal results is 
difficult to determine. One study reported IgG and IgM anticardiolipin antibodies in 
approximately 5% of normal individuals, although only 2% had persistently elevated levels on 
repeat testing. Shi and colleagues detected anticardiolipin antibodies in 6% of normal blood 
donors, respectively, and detected lupus anticoagulant activity by kaolin clotting time in 
4%Shi W 1993). The prevalence of anticardiolipin antibody appears to increase with age. 
The prevalences of elevated levels of IgG and IgM anticardiolipin antibody in healthy 
pregnant women were 2% to 3% and 4%, respectively(Harris EN 1991, Aoki K 1994, 
Lockshin MD 1997). Most of these were low titer; only 0.2% were high titer. In other studies, 
the incidence of anticardiolipin antibodies in pregnant individuals ranged from 1% to 2% 
and lupus anticoagulant 1% to 4%(Petri M 2000). 
When the patient does not exhibit any other symptom that would allow the diagnosis of 
another associated autoimmune disease, the antiphospholipid syndrome is considered 
primary, or isolated. The term ‘secondary’ APLS is sometimes used for patients suffering 
from another autoimmune or inflammatory disease.  
3. Etiopathogenesis 
Lupus anticoagulants and anticardiolipin antibodies are immunoglobulins that were 
originally thought to react only with phospholipid. However, it is now well established that 
these antibodies react directly with epitopes on ǃ2-GPI(McNeil HP 1990, Galli M 1990) or 
prothrombin(Rao LVM 1996, Bevers EM 1991 ), that subsequently bind to anionic 
phospholipid. Anticardiolipin antibodies are low-affinity monovalent antibodies to ǃ2-GPI 
when in solution, and the monovalent complexes bind weakly to anionic phospholipids. 
However, when the antigen density is high, bivalent complexes are formed that have a high 
affinity for phospholipid surfaces. The fact that ǃ2-GPI antibodies are polyclonal reacting 
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with different epitopes on the ǃ2-GPI molecule and the increased affinity of the divalent 
antigen-antibody complexes for phospholipid surfaces explains why some anticardiolipin 
antibodies have anticoagulant activity and some do not(Arnout J 2003). This anticoagulant 
activity correlates best with the incidence of thrombosis(Galli M 2003), and a subset of lupus 
anticoagulants caused by anti–ǃ2-GPI antibodies with specificity for an epitope on domain I. 
In some patients the anticardiolipin antibody will react with immobilized cardiolipin in 
vitro but not prolong phospholipid-dependent coagulation tests. Similarly, some of the 
antiprothrombin antibodies can prolong coagulation tests and some will not. 
As with most autoimmune conditions, the etiology of APLS is not understood. It has been 
demonstrated that normal healthy individuals without APS have memory B cells that 
produce aPL antibodies; in a study of patients with infectious mononucleosis, 10 to 60 
percent of immunoglobulin M aCL-producing cells expressed CD 27, the marker of memory 
B cells(Lieby P 2003).  
Although antibodies against anionic phospholipid moieties arise during the course of 
infections such as syphilis and lyme disease, those are distinct from antibodies generated by 
patients with the syndrome because they generally recognize phospholipid epitopes directly 
and are not associated with the clinical manifestations of the syndrome. 
Reports of familial clustering of raised aPL antibody levels indicate that genetic 
susceptibility can play a role in their development(Donald I. Feinstein 2007). In one study of 
84 APLS patients, more than 35% had at least one relative, and more than 20% had two or 
more relatives, with evidence of at least one clinical feature of APS, such as thrombosis or 
recurrent fetal loss(Weber M 2000). 
Many different mechanisms have been described for thrombosis during APLS, mainly after 
in-vitro experiments: (1) activation of endothelial cells by complexes of ǃ2 GPI and anti-ǃ2 
GPI, these complexes could bind to annexin 2 or even Toll-like receptors on the surface of 
endothelial cells(Zhang J 2005, Fischetti F 2005); (2) platelet activation after direct binding of 
the ǃ2 GPI, which targets the autoantibodies on the surface of these cells, the ǃ2 GPI is 
selectively bound by the activator receptor apo ER 2(Lutters BC 2003); (3) functional 
dysregulation of hemostasis by the presence of autoantibodies against natural anticoagulant 
proteins like annexin 5 and activated protein C; (4) abnormal fibrinolysis directly linked to 
the presence of APL(Cesarman-Maus G 2006). 
APL can stimulate platelet aggregation(Lin YL 1992), an effect that might be promoted via 
signalling through apolipoprotein E receptor 2(apoER2) receptors; the beta2GPI binding site 
for apo ER2 on platelets was localized to its domain V. Beta2GPI also has a dampening effect 
on platelet adhesion by interfering with the platelet-von Willebrand factor interaction, and 
consequently aPL antibodies, by interfering with this dampening, can increase platelet 
adhesion in flow systems(Hullstein JJ 2007). 
Normal endothelial function includes control over thrombosis and thrombolysis, platelets 
and leukocyte interaction with the vessel wall, and regulation of vascular tone and smooth 
muscle proliferation. Several in vitro studies and studies on animal models have shown that 
incubation of endothelial cells with aPL from APLS patients generates different effects on 
endothelial function via ǃ2 GPI. As a whole this might cooperate in sustaining endothelial 
perturbation that has been suggested to have a pivotal pathogenetic role in APS associated 
thrombosis(Stalc  M 2006).  
Because high-level aPLs may persist for years in asymptomatic persons, it is likely that 
vascular injury, endothelial cell activation, or both immediately precede the occurrence of 
thrombosis in those bearing the antibody (second-hit hypothesis). Of note, at least 50% of 
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APLS patients with vascular factors possess other acquired thrombosis risk factors at the 
time of their events(Kaul M 2006, Erkan D 2002). 
Both persons congenitally lacking ß2GPI39 and ß2GPI knockout mice appear normal(Sheng 
Y 2001).  ß2GPI polymorphisms influence the generation of aPLs in individuals, but they 
have only a weak relationship to the occurrence of APLS. A cluster of 50 upregulated genes 
may have an effect on the occurrence of thrombosis in aPL-positive individuals(Potti A 
2006). 
4. Diagnostic criteria of the antiphospholipid syndrome 
The international preliminary classification criteria for APLS was published in 1999 after a 
workshop in Sapporo, Japan(Wilson WA 1999)-the so-called Sapporo criteria-. It was 
updated in 2006 after another workshop in Sydney, Australia(Miyakis S 2006). (table 1). 
 
Clinical criteria 
 
1. Vascular thrombosis 
One or more clinical episodes of arterial,venous or small vessel thrombosis, in any tissue 
or organ. 
2. Pregnancy morbidity 
a. One or more unexplained deaths of a morphologically normal fetus at or beyond 
the 10th week of gestation, or 
b. One or more premature births of a morphologically normal neonate before the 
34th week of gestation because of eclampsia, severe preeclampsia, or recognized 
features of placental insufficiency, or 
c. Three or more unexplained consecutive spontaneous abortions before the 10th 
week of gestation, with maternal anatomic or hormonal abnormalities and 
paternal and maternal chromosomal causes excluded. 
Laboratory criteria 
 
1. Lupus anticoagulant present in plasma, on 2 or more occasions at least 12 weeks 
apart, detected according to the guidelines of the International Society on 
Thrombosis and Hemostasis 
2. Anticardiolipin antibody of IgG and/or IgM isotype in serum or plasma, present in 
medium or high titer(ie, >40 GPL or MPL, or greater than the 99th percentile),on 2 or 
more occasions at least 12 week apart, measured by a standardized ELISA. 
3. Anti-ǃ2-glycoprotein I antibody of IgG and/or IgM isotype in serum or plasma(in 
titer greater than the 99th percentile) present one or more occasions, at least 12 week 
apart, measured by a standardized ELISA. 
***Definite APLS is present if at least one of the clinical criteria and one of the laboratory criteria are 
met. Classification of APLS should be avoided if less than 12 weeks or more than 5 years seperate the 
positive APL test and the clinical manifestation. 
Table 1. Updated Sapporo classification criteria for the antiphospholipid syndrome 
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The first clinical aspect of the APLS is thrombosis, which can affect arterial or venous 
vessels, as well as small vessels, and must be confirmed by means of imaging studies 
and/or histopathology. Arterial thrombosis mainly occurs in the central nervous system. 
But all arteries can be effected and myocardial infarction, peripheral gangrene, aseptic 
osteonecrosis and adrenal insufficency can develop with respect to effected arterial site. The 
venous thrombosis commonly localizes to the deep veins of the limbs and can be 
complicated by pulmonary embolism. As in arterial thrombosis, any segment of the venous 
vasculature can be effected, which will induce different manifestations. 
A definitive diagnosis of APLS is based on fulfilling at least one of the Updated Sapporo 
Clinical criteria(vascular thrombotic event or pregnancy morbidity) and at least one of the 
laboratory criteria(Table 1). In general, medium titer aCL is considered 40 U or more and 
high titer, more than 80 U; titers between 20 and 40 U should be evaluated cautiously. 
Transient APL positivity is common during infections; thus documentation of the 
persistence(at least 12 weeks apart) of autoimmune APL is crucial for both diagnostic and 
therapeutic purposes.  
The choice of initial APL tests remains a subject of debate. In general, the LA test is more 
specific for APL-related clinical events. The specificity of aCL for APL-related clinical events 
increases with higher titers. The IgG isotype is more strongly associated with APL-related 
clinical events than the IgM isotype. In a patient with suspected APS, testing for LA and 
IgG/IgM aCL should be ordered initially. If these tests are negative or low-titer and there is 
still a high level of suspicion for APS, then testing for antiǃ2GPI antibodies and IgA 
aCL/antiǃ2GPI can be pursued(George D 2009). Antiphospholipid antibody tests developed 
based on other phospholipids such as phosphatidylserine, phosphatidylinositol, or 
phosphatidylethanolamine or phospholipid-binding plasma proteins(such as prothrombin) 
are not yet well standardized and accepted. 
5. Clinical features 
Although any vasculature can be affected by thrombosis, stroke and transient ischemic 
attack are the most common presentations of arterial thrombosis, whereas deep vein 
thrombosis with or without pulmonary embolism is the most common presentation of 
venous thrombosis in APLS(George D 2009). Antiphospholipid antibodies can cause both 
arterial and venous thrombosis in the same patient. Reccurent thromboses tend to occur in 
the same vascular distribution(venous followed by venous and arterial followed by arterial). 
in some studies the incidence of venous thrombosis (70%) is greater than the incidence of 
arterial thrombosis.(Galli M 1997, Triplett DA 1995). 
Superficial thrombophlebitis, superior vena cava syndrome, renal vein thrombosis, Budd 
Chiari syndrome, central retinal vein occlusion, pulmonary hypertension due to recurrent 
pulmonary embolism, and diffuse pulmonary hemorrhage due to microthrombosis are 
some of the thrombotic manifestations of APLS. 
Of unselected patients with antiphospholipid antibody, 1% to 2.5% per year will develop 
thromboembolism(Galli M 2003, Finazzi G 1996),and 10% to 25% of patients with deep 
venous thrombosis will be found to have antiphospholipid antibodies(Ginsburg KS 
1992).However, in a prospective population based study of 66140 individuals in 
Norway(Naess IA 2005), elevated anticardiolipin antibody levels were not a risk factor for 
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predicting an initial venous thrombosis. Thrombosis is more frequent as the level of 
anticardiolipin antibody increases, and medium and high titers (>40 GPL and/or MPL 
units) are more frequently associated with thrombotic events. Although some investigators 
believe that elevated levels of IgG or IgA isotypes are more common than IgM in patients 
with thrombotic complications, this has not been clearly established. The lupus 
anticoagulant or increased levels of anticardiolipin antibody must be persistently present on 
more than one occasion at least 12 weeks apart because the incidence of thrombotic 
complications is almost the same in patients with transiently positive tests as in patients 
with negative tests at two different time intervals. The persistent presence of elevated levels 
of anticardiolipin antibody has been shown to be associated with indices of in-vivo 
coagulation activation. In a study of patients with SLE(Ginsberg JS 1993) who were 
persistently anticardiolipin antibody– positive versus patients who were transiently positive 
or persistently negative, anticardiolipin antibody–positive patients had a higher mean level 
of F1+2 and fibrinopeptide A than patients who were transiently positive, persistently 
negative, or on warfarin therapy. The differences remained significant even if patients with 
prior thromboembolism were excluded from the analysis. These results suggest that the 
presence of persistently elevated levels of anticardiolipin antibody in SLE patients is 
associated with an ongoing prothrombotic state. 
Patients who are persistently positive for the lupus anticoagulant or who have persistently 
elevated levels of anticardiolipin antibody and suffer a thromboembolic event have a 
recurrence rate of approximately 50% within 2 years(Rosove MH 1992, Khamashta MA 
1995). Recurrences tend to occur in most of the patients on the same side of the circulation as 
the initial event—venous recurrences after an initial venous event and arterial recurrences 
after an initial arterial event. 
6. Treatment of venous thrombosis in APLS  
6.1 General treatment 
The standard of care for venous thromboembolism is continous infusion of intravenously 
delivered unfractionated heparin(UFH) and, more recently, subcutaneous low-molecular 
weight heparins(LMWH). DVT is associated with several possible complications, including 
recurrent nonfatal venous thromboembolism, postthrombotic chronic venous insufficiency, 
and nonfatal/fatal pulmonary embolism. The goals of therapy for DVT include the 
prevention of thrombus propagation, embolization, and early and late thrombus recurrence. 
Proper anticoagulation is the first critical step in the effective treatment of DVT. 
Complications can develop soon after thrombus detection, presenting a narrow window of 
opportunity for a safe and effective intervention. The secondary stage of treatment involves 
the maintenance of adequate anticoagulation to prevent the development of recurrent 
thromboembolism. 
LMWH or fondaparinux is preferred for the initial anticoagulation of patients with deep 
vein thrombosis(Table 2). LMWH and fondaparinux are as safe and as effective as 
continuous unfractionated heparin (UFH). Suitable patients can be safely treated with 
LMWH and fondaparinux in the outpatient setting. Heparin/fondaparinux should be 
continued for at least five days after the initiation of warfarin therapy and until 
International Normalized Ratio (INR) is > 2.0 for two consecutive days. Warfarin should be 
initiated 5 mg on day 1. 
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Treatment for venous thromboembolism with LMWH provides reliable anticoagulation 
levels when given subcutaneously on a weight-based dosing schedule. No laboratory 
monitoring of the intensity of anticoagulation is required for LMWH, except in special 
circumstances. Recent randomized controlled trials of the treatment of pulmonary 
embolism (PE) have shown LMWH to be as effective and safe as UFH. One randomized 
controlled trial of the treatment of venous thromboembolism (VTE) in 1,021 patients 
included 271 patients presenting with PE. In this study, there were no significant 
differences in outcomes following  treatment with UFH versus LMWH. These studies 
used reviparin and tinzaparin. Two reviews agreed that LMWH may be efficacious in the 
treatment of PE, but cautioned that the LMWH products may not be equivalent to each 
other (Raskob 1999 ; Charland, 1998; Columbus Investigators, 1997; Simonneau, 1997). 
LMWH may not be appropriate for patients with renal insufficiency (creatinine clearance 
less than 30 mL/min). Studies have shown modestly delayed clearance in patients with 
chronic renal failure. The clinician should weigh this evidence when considering outpatient 
therapy. 
A high-loading dose of warfarin (greater than 10 mg) is of no clinical use and should be 
discouraged.  A 10 mg initial dose of warfarin has been associated with early over-
anticoagulation and, when compared to a 5 mg initial dose, was no more effective in 
achieving a therapeutic international normalized ratio (INR) by day four or five of therapy. 
A therapeutic range of anticoagulation to keep the INR at 2.5 (range 2.0-3.0) is 
recommended for patients with venous thromboembolism. Heparin and warfarin may be 
started at the same time. The anticoagulant effect of warfarin is delayed until clotting factors 
already circulating are cleared. Although Factor VII has a shorter half-life in the blood (six to 
seven hours), peak anticoagulant activity is delayed for up to 96 hours until factors with 
longer plasma half-lives (II, IX and X) have cleared . Heparin (UFH or LMWH) and warfarin 
may be started at the same time. Heparin (UFH or LMWH) and/or fondaparinux should be 
given for a minimum of five days. Patient should continue heparin until INR >=2.0 for two 
consecutive days. In patients with suspected hypercoagulable state (Protein C or Protein S 
deficiency), the patient should be adequately anticoagulated with heparin (UFH or LMWH) 
and/or fondaparinux before warfarin is started at a low dose (2-5 mg). This is to avoid 
warfarin-induced skin necrosis or other transient hypercoagulable complications. 
Recommendations for the management of thrombosis in the APLS have been based largely 
on retrospective case series. Recently, several clinical trials have been published on the 
management of thrombosis in APLS.These new clinical trials have challenged the previous 
dogma of a target INR of 3 to 4(high-intensity warfarin). 
6.2 Primary prophylaxis of thrombosis in patients with APL antibodies 
The therapeutic approach in asymptomatic carriers of APL without prior thrombotic 
events is still controversial. Present evidence-based knowledge does not support the 
widespread use of aspirin in all these aPL-positive patients. Annual thrombosis risk in 
asymptomatic APL-positive patients range from 0% to 3.8%( Finazzi G 1996, Shah NM 
1998), being equivalent to that of major bleeding associated with the use of aspirin. The 
only randomized clinical trial (APLASA study) in which 98 asymptomatic persistently 
APL-positive individuals were randomized to recieve a daily dose of 81 mg of aspirin or 
placebo showed that these patients have a low overall annual incidence rate of acute 
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thrombosis, and develop vascular events when additional risk factors are present(Erkan D 
2007). Therefore, according to the results of this trial, asymptomatic, persistently APL-
positive individuals seem not to benefit from low-dose aspirin for primary 
thromboprophylaxis.  
However, a more realistic approach with a lower degree of evidence  would be to stratify 
these individuals according to some clinical features such as the presence of traditional 
congenital or acquired procoagulant risk factors, the APL profile(persistently positive aCL 
and or anti-ǃ2GPI antibodies at moderate/high titers), and the coexistence of an 
underlying autoimmune disease, to consider primary prophylactic therapy with low-dose 
75-100 mg aspirin daily. It is known that SLE represents a prothrombotic condition and 
acts as strong thrombophilic risk factor, primarily related to the chronic systemic 
inflammation and renal involvement. Furthermore, one study has shown that 
prophylactic aspirin should be given to all patients with SLE to prevent both arterial and 
venous thrombotic manifestations, especially in patients with APL(Wahl DG 2000). In the 
same study, the authors suggested that in selected patients with LA and a low bleeding 
risk, prophylactic oral anticoagulant therapy may provide higher utility. Therefore, there 
is currently consensus for primary thromboprophylaxis in these patients, mainly with 
low-dose aspirin. 
An alternative to aspirin in SLE patients may be hydroxychloroquine. There are many 
evidences for the protective role of this old drug against the development of both venous 
and arterial thrombosis(Ruiz-Irastorza G 2006, Erkan D 2002). 
All nonthrombotic APL-positive subjects should be encouraged to stop smoking. Cessation 
of  oestrogen –containg oral contraceptive use and treatment of other vascular risk factors if 
present are additional recommended therapeutic measures. 
At least half of patients with APLS with vascular events also have another reversible risk 
factors which are not related to APLS at time of thrombosis(Erkan D 2002). Therefore, 
identification and elimination of these risk factors and agressive prophylaxis during high-
risk periods, are crucial for the primary thrombosis prevention in asymptomatic persistently 
APL-positive individuals. Serious perioperative complications including catastrophic 
antiphospholipid syndrome(CAPS) may occur despite prophylaxis in APL-positive 
individuals as they are at additional risk for thrombosis when undergoing surgical 
procedures. Therefore, perioperative strategies should be clearly identified before any 
surgical procedure, pharmacological, and physical antithrombosis interventions should be 
vigorously used; periods without anticoagulation should be kept to an absolute 
minimum(George D 2009). 
6.3 Therapy for acute thrombosis and secondary propylaxis of thrombosis in patients 
with antiphospholipid syndrome 
Therapy for thrombosis associated with the  APLS should be guided by the knowledge that 
recurrence is common. In one study, patients who had discontinued oral anticoagulation 
had a 50% probability of recurrence in 2 years and a 78% recurrence in 8 years(Derksen 
RHWM 1993). Similar results have been published by others with a recurrence rate of 10% 
to 30% per year(Galli M 2003, Rosove MH 1992, Khamashta MA 1995). Three prospective 
studies reported that there was an increased risk of recurrence that varied from 10% to 
67% per year(Lim W 2006, Schulman S 1998, Kearon C 1999, Kearon C 2003, Ortel TL 
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2005). In most reports the incidence of recurrence is highest in the first 6 months after 
discontinuing anticoagulant therapy.  Although it was initially thought that prevention of 
venous recurrence required high-intensity warfarin with a target INR of 3.5, evidence has 
been accumulating from recent studies that standard intensity warfarin (INR 2 to 3) can 
almost completely abrogate recurrence of venous thromboembolic disease(Crowther MA 
2003, Finazzi G 2005). The pooled data from these two studies revealed no difference in 
recurrent thrombosis between moderate-intensity warfarin (INR 2 to 3) and high-intensity 
(INR 3 to 4), nor was there a greater bleeding risk. As the data from several studies have 
demonstrated that patients with antiphospholipid syndrome have a high risk for 
recurrent venous thromboembolic disease after anticoagulation is discontinued, many feel 
that anticoagulation should be continued indefinitely. The American College of Chest 
Physicians recommends treatment for 12 months and consideration of indefinite therapy 
after an initial event(Ortel TL 2005, Buller HR 2004). Because of the efficacy of warfarin 
therapy in preventing recurrences, the use of corticosteroids and other 
immunosuppressive agents to suppress antibody production in the absence of 
autoimmune disease is not recommended.  
 
- Objectively confirm DVT; provide short-term treatment with SC LMWH or IV UFH 
or SC UFH(1A) 
- High clinical suspicion for DVT: treat until diagnosis is confirmed(1C) 
- Initial treatment LMWH or UFH for ≥5 days 
- Warfarin should be started on the first day of treatment  
- IV UFH by weight based or standard dosing to achieve and maintain an aPTT 
prolongation that corresponds to plasma heparin levels of 0.3 to 0.7 IU/mL anti-Xa 
activity(1C) 
- UFH with large doses:measure anti-Xa to adjust dose(1B) 
- SC UFH at a dose of 17500 U,SC, Q 12 hours or 250 U/kg, sc, Q 12 hours with 
adjustment to achieve a therapeutic aPTT(1C). 
- SC fixed dose UFH at a dose of 333 U/kg, sc, Q 12 hours without monitoring for 
adjustment of dose(1C). 
- SC LMWH once or twice daily over UFH as an outpatient if possible(1C) or as an 
inpatient(1A). 
- Reccomend against monitoring with anti-Xa levels(1A). 
- Severe renal failure: suggest IV UFH over LMWH(2C). 
Table 2. Venous thromboembolism(VTE) treatment guidelines adapted from the American 
College of Chest Physicians  Evidence –based clinical practice guidelines-8th edition 
Monitoring anticoagulant therapy may be difficult in patients with lupus anticoagulants and 
a prolonged PTT. It is mandatory when using unfractionated heparin to monitor therapy 
using a specific heparin assay, such as the one dependent on factor Xa inhibition 
(therapeutic range, 0.3 to 0.7). In most instances, it is preferable to use low-molecular-weight 
heparin in therapeutic doses, which usually eliminates the need for monitoring. When using 
warfarin, the optimal INR for patients with lupus anticoagulants is controversial, because 
patients with lupus anticoagulants may have a variably prolonged prothrombin time,and 
various thromboplastins have a different sensitivity in the presence of a lupus 
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anticoagulant.Therefore, it is possible that in various studies of therapy in patients with 
lupus anticoagulants that the degree of anticoagulation is overestimated, and the target INR 
of 3.0 noted earlier might be an overestimate because of the presence of the lupus 
anticoagulant(Donald I. Feinstein 2007). Rarely, patients may continue to have recurrent 
venous thromboembolic events despite INR values in the therapeutic range. Recurrent 
thrombotic events despite therapeutic anticoagulation require evaluation and modification 
of all non-APL thrombosis risk factors. Warfarin therapy is generally increased to high-
intensity(INR, 3.0-4.0). Other options include adding low-dose aspirin, hydroxychloroquine, 
and/or statins to warfarin or switching to low-molecular weight heparin. There are no 
randomized controlled studies investigating the effectiveness of any of these approaches. 
Based on many cohort studies ,subgroup analysis and two randomized controlled studies, a 
recent review(Ruiz-Irastorza G  2007) suggests that patients with definite APLS with a first 
venous thrombosis should be treated with prolonged oral anticoagulation at a target INR of 
2.0-3.0 and those with an arterial event at an 3.0-4.0.  
So, the best secondary thromboprophylaxis in patients with definite APLS  is long-term 
anticoagulation at a target INR of 2.0-3.0. Patients with recurrent venous thrombotic events 
despite optimal anticoagulation should be treated with warfarin at an INR of 3.0-4.0. 
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